Protara Therapeutics Stock Performance
| TARA Stock | USD 3.01 0.03 0.99% |
On a scale of 0 to 100, Protara Therapeutics holds a performance score of 14. The company holds a Beta of 0.13, which implies not very significant fluctuations relative to the market. As returns on the market increase, Protara Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Protara Therapeutics is expected to be smaller as well. Please check Protara Therapeutics' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Protara Therapeutics' historical price patterns will revert.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Protara Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Protara Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.99) | Five Day Return 24.38 | Year To Date Return 43.33 | Ten Year Return (99.28) | All Time Return (99.25) |
Last Split Factor 1:40 | Dividend Date 2020-01-10 | Last Split Date 2020-01-10 |
1 | Insider Trading | 09/05/2024 |
2 | Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations | 09/09/2024 |
3 | Disposition of 1500 shares by Opaleye Management Inc. of Protara Therapeutics at 1.769 subject to Rule 16b-3 | 09/10/2024 |
4 | Disposition of 1600 shares by Opaleye Management Inc. of Protara Therapeutics at 1.7141 subject to Rule 16b-3 | 09/11/2024 |
5 | Variscite and Embedded Wizard by TARA Systems Integrate Advanced GUIs in SoMs to Speed Development and Time to Market | 09/24/2024 |
6 | Cure Alzheimers Fund Receives 338,384 Donation from Tara Manufacturing | 10/10/2024 |
7 | Disposition of 3500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4419 subject to Rule 16b-3 | 10/30/2024 |
8 | Disposition of 2500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.1233 subject to Rule 16b-3 | 11/08/2024 |
9 | Protara Therapeutics Reports Increased RD Expenses - TipRanks | 11/13/2024 |
10 | Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - GuruFocus.com | 11/18/2024 |
11 | Global Human Growth Hormones Market to Reach USD 10 Billion by 2030 DelveInsight | 11/27/2024 |
| Begin Period Cash Flow | 24.9 M |
Protara |
Protara Therapeutics Relative Risk vs. Return Landscape
If you would invest 192.00 in Protara Therapeutics on September 1, 2024 and sell it today you would earn a total of 109.00 from holding Protara Therapeutics or generate 56.77% return on investment over 90 days. Protara Therapeutics is currently generating 0.8063% in daily expected returns and assumes 4.3376% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Protara, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Protara Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protara Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Protara Therapeutics, and traders can use it to determine the average amount a Protara Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1859
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TARA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.34 actual daily | 38 62% of assets are more volatile |
Expected Return
| 0.81 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.19 actual daily | 14 86% of assets perform better |
Based on monthly moving average Protara Therapeutics is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Protara Therapeutics by adding it to a well-diversified portfolio.
Protara Therapeutics Fundamentals Growth
Protara Stock prices reflect investors' perceptions of the future prospects and financial health of Protara Therapeutics, and Protara Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protara Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | (14.67 M) | ||||
| Shares Outstanding | 20.63 M | ||||
| Price To Book | 0.76 X | ||||
| EBITDA | (43.27 M) | ||||
| Net Income | (40.42 M) | ||||
| Cash And Equivalents | 98.46 M | ||||
| Cash Per Share | 8.74 X | ||||
| Total Debt | 5.47 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 28.94 X | ||||
| Book Value Per Share | 6.01 X | ||||
| Cash Flow From Operations | (37.56 M) | ||||
| Earnings Per Share | (2.64) X | ||||
| Market Capitalization | 62.1 M | ||||
| Total Asset | 78.95 M | ||||
| Retained Earnings | (200.38 M) | ||||
| Working Capital | 62.56 M | ||||
About Protara Therapeutics Performance
By analyzing Protara Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Protara Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Protara Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protara Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.5 K | 839 | |
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.60) | (0.63) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.59) | (0.62) |
Things to note about Protara Therapeutics performance evaluation
Checking the ongoing alerts about Protara Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protara Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (40.42 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protara Therapeutics currently holds about 98.46 M in cash with (37.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Protara Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Global Human Growth Hormones Market to Reach USD 10 Billion by 2030 DelveInsight |
- Analyzing Protara Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protara Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protara Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protara Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protara Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protara Therapeutics' stock. These opinions can provide insight into Protara Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Protara Stock analysis
When running Protara Therapeutics' price analysis, check to measure Protara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protara Therapeutics is operating at the current time. Most of Protara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protara Therapeutics' price. Additionally, you may evaluate how the addition of Protara Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |